In reply: The epinephrine solutions used in this study were as follows: 1) E (1:200,000 epinephrine in normal saline solution) prepared by diluting 1:1000 epinephrine with normal saline—pH = 6.1; and 2) LE (1:200,000 epinephrine with 0.5% lidocaine) prepared by diluting a commercially available 1% lidocaine containing 1:100,000 epinephrine (Astra, Fujisawa) with normal saline—pH = 4.9.

Thus, the differences of these solution could partly be responsible for the variation in epinephrine uptake as indicated by Sosis and Temple. Further study is needed to identify the respective roles of pH and lidocaine on absorption of epinephrine.

WASA UEDA, M.D.
Associate Professor of Anesthesiology
Kochi Medical School
Kochi, 781-51, Japan

(Accepted for publication February 10, 1986)

Concerning Assay of Serum Cholinesterase with Succinylcholine

To the Editor:—The recent publication of a method for measuring serum cholinesterase using succinylcholine as the substrate requires comment. Although the authors claim that this is "a new enzymatic method for assaying cholinesterase activity," we had published an assay using the same principle more than a year earlier. Our procedure reliably identifies individuals at risk of suxamethonium apnea and is suitable for use as a preoperative screen.

There are a number of serious problems in the analytical procedure published by Wakid et al. In particular, they use a reagent blank in which water rather than serum is added. This is unsatisfactory as it does not allow for the nonspecific catalysis hydrolysis of succinylcholine by substances other than cholinesterase. Clearly, their reagent blank would be better replaced by a serum blank in which cholinesterase is inhibited by physostigmine. Their assay measures hydrolysis of succinylcholine in the presence of phenol and aminoantipyrine; however, our experimental work endeavoring to develop a kinetic procedure showed that these are both inhibitors of cholinesterase. Even though their phenol and aminoantipyrine concentrations are slightly lower than our lowest concentration in table 1, there will still be significant interference. These problems are overcome by performing the assay in two stages, viz: 1) enzymatic hydrolysis of succinylcholine; 2) inhibition of cholinesterase by physostigmine and determination of the choline produced.

Although Wakid et al. have assayed cholinesterase in the presence of these inhibitors, they paradoxically obtain average enzyme activities comparable with those by our two-stage method. This is probably explained by their invalid calibration system. Their assay was apparently standardized when "serum was replaced by water, and succinylcholine by choline chloride." Their choice of choline chloride was unwise as it is extremely deliquescent and therefore cannot be used; the nondeliquescent choline iodide should have been used. Further, their calibration system cannot apply to a kinetic assay; it is appropriate only to an end-point assay. This is because the rate of the reaction of the standard depends on the initial high choline concentration, whereas, in the serum samples choline is continually being generated. A valid standard reflecting the kinetic analysis would be to use a serum sample pre-calibrated by our two-stage method.

Fortuitously, an increase in "cholinesterase activity" due to the standardization procedure is apparently compensated for by the loss of activity due to performing the assay in the presence of the inhibitors phenol and aminoantipyrine. Although the method, as published, cannot be recommended, the kinetic approach has obvious potential for automation if these problems can be overcome.

---

**Table 1. Interference of Phenol and Aminoantipyrine with Cholinesterase**

<table>
<thead>
<tr>
<th>Inhibitor</th>
<th>Inhibitor Concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Low†</td>
</tr>
<tr>
<td>Phenol</td>
<td>91‡</td>
</tr>
<tr>
<td>Aminoantipyrine</td>
<td>95</td>
</tr>
<tr>
<td>Phenol + aminoantipyrine</td>
<td>84</td>
</tr>
</tbody>
</table>

* Phenol 20 mmol/l, aminoantipyrine 4 mmol/l.
† Phenol 1 mmol/l, aminoantipyrine 0.2 mmol/l.
‡ Activity as a percentage of a normal plasma pool in the absence of any inhibitors (determined as ref. 1).
CORRESPONDENCE

PETER M. GEORGE, M.B. B.S.
MAXWELL H. ABERNETHY, B.SC.
JEAN L. HERRON, M.B. CH.B.
Department of Clinical Biochemistry
Christchurch Hospital
Christchurch, New Zealand

REFERENCES

Anesthesiology
05:105, 1986

In reply.—We were pleased to learn that we are not the only laboratory using an enzymatic method for the assay of cholinesterase with succinylcholine as a substrate. Because our kinetic approach is more practical than assaying in stages, however, we would like to provide further clarification of our procedure.

The use of water in the reagent blank instead of serum does not contribute to any serious error due to nonspecific hydrolysis by “substances other than cholinesterase.” This is because hydrolysis of both succinylcholine and succinylmonocholine is catalyzed by the same enzyme, i.e., cholinesterase,1 and because only a small fraction of the succinylcholine present (2-6% of 0.5 μmol) is hydrolyzed to succinylmonocholine. The enzyme is therefore acting mainly on the dicholine ester during the first 10 min of our assay. The contribution of the rate of choline formation by succinylmonocholine is therefore negligible because it is hydrolyzed more slowly than the dicholine ester.1 Evidence that nonspecific hydrolysis of succinylcholine is not serious can be seen by the extremely low activities of the E1, E1, and E1, E1, genotypes.

Phenol and, especially, aminooantipyrine are indeed inhibitory. The latter, at the concentration we use, produces a 20% inhibition of cholinesterase when assayed by the propionylthiocholine method. The concentrations we use are optimal, i.e., activity decreases at higher and lower concentrations.* If the conditions for assay are consistently adhered to, the inhibitory effect of the dye may be disregarded because it would be the same for low as well as high enzyme activities. We have obtained a linear relationship between activity and enzyme concentration up to 250 U/l, and this should provide ample validation of the test. (Here, we apologize for an error in our paper. On page 510, second column, third paragraph from the bottom, please read 250 U/l instead of 25 U/l.)

We agree that the nondeliquescent choline iodide would be preferable to choline chloride for calibration. The calibration itself is necessarily an endpoint assay as can be seen in figure 2 of our paper: in the absence of cholinesterase there are no steady-state rates to measure. The reaction is virtually complete in 3 to 4 min. We wait at least 10 min before taking the absorbance reading.

Differences between the “average” cholinesterase activity of a population, or reference value, are bound to occur between laboratories. We recommend that every laboratory establish its own reference values.

NABIL W. WAKID, PH.D.
RAMZI TUBBEH, M.S.
ANIS BARAKA, M.D.
Department of Laboratory Medicine
Department of Biochemistry
Department of Anesthesiology
American University of Beirut

REFERENCE

(Received for publication February 10, 1986.)